



#### International Scientific Committee

- Jacques J.M. van Dongen (chair)
- Monika Brüggemann
- Gianni Cazzaniga
- Patricia Groenen
- Jerry Hancock
- Marco Ladetto
- Ton Langerak
- Alberto Orfao
- Beat Schäfer
- Tomasz Szczepanski
- Jan Trka
- Neus Villamor

#### Local Organizing Committee

- J.J.M. van Dongen
- W.M. Bitter
- B. Beukenkamp

#### Information and registration

Erasmus MC - het Congresbureau  
Bernice Beukenkamp  
E-mail: [b.beukenkamp@erasmusmc.nl](mailto:b.beukenkamp@erasmusmc.nl)  
[www.hetcongresbureau.nl](http://www.hetcongresbureau.nl)  
[www.eslho.org](http://www.eslho.org)

Registration fee (including Conference Dinner): €225

#### Scientific Working Group of:



■ ■ ■ ■ EuroMRD ●●● EuroClonality EuroFlow

[www.ESLHO.org](http://www.ESLHO.org)



## 6<sup>th</sup> ESLHO Symposium MRD and Immune-monitoring in Hemato-Oncology

9-10 November 2017  
Corpus Congress Centre, Leiden, NL

## Thursday, 9 November 2017

12:00 – 13:00 Registration and Lunch

13:00 – 13:05 Welcome – Jacques J.M. van Dongen

### 13:05 – 15:00 **Session 1: MRD in acute lymphoblastic leukemia (ALL)**

*Chair: Monika Brüggemann and Jan Trka*

- NGS-based MRD technology: a specific tool for prospective MRD monitoring  
*Jan Trka, Prague, CZ*
- How to measure MRD in the era of targeted treatment  
*Monika Brüggemann, Kiel, DE*
- Improved outcome by better risk group definition in childhood ALL: comparison between Dutch and BFM approaches in treatment reduction  
*Rob Pieters, Utrecht, NL*
- ALL together: integrated risk stratification in ALL: response and genetics  
*John Moppett, Bristol, UK*
- Adult ALL: how to use MRD measurements for stratification of new treatment modalities  
*Joseph Maria Ribera, Bandalona, ES*
- Abstract based presentation  
(15 min)

15:00 – 15:20 Short coffee break

### 15:20 – 16:50 **Session 2: MRD in acute myeloid leukemia (AML)**

*Chair: Oliver Ottmann and Konstanze Döhner*

- Introduction on MRD in AML: what can we learn from ALL?  
*Oliver Ottmann, Cardiff, UK*
- Molecular MRD detection: Technical overview in AML and its clinical application  
*Adam Ivey, Melbourne, AU*
- Flowcytometric MRD detection: the myeloid stem cell/AML stem cell approach  
*Gerrit Jan Schuurhuis, Amsterdam, NL*
- How to implement MRD detection in clinical AML trials  
*Konstanze Döhner, Ulm, DE*
- Abstract based presentation  
(15 min)

16:50 – 17:10 Short coffee break

### 17:10 – 18:45 **Session 3: MRD in multiple myeloma (MM)**

*Chair: Brian Durie and Alberto Orfao*

- New response criteria in multiple myeloma: how to integrate complementary MRD approaches  
*Brian Durie, Los Angeles, US*
- Heavy-light chain monitoring in plasma vs flow MRD in the BM in MM  
*Ruth the Tute, Leeds, UK*
- Clinical impact of MRD by conventional flow vs NGF in MM  
*Bruno Paiva, Pamplona, ES*
- Abstract based presentation  
(15 min)

19:30 – 23:00 *Dinner at Hoogland Church, Leiden (free for all registered participants)*

## Friday, 10 November 2017

### 08:30 – 10:00 **Session 4: MRD in mature lymphoid malignancies**

*Chair: Christiane Pott and Marco Ladetto*

- MRD trials in mature lymphoid malignancies  
*Marco Ladetto, Alessandria, IT*
- Use of cell-free tumor DNA (ctDNA) in plasma or cellular DNA from BM and/or PB: which strategy for tissue-born lymphomas  
*Davide Rossi, Bellinzona, CH*
- Occult CNS involvement by flow cytometry in aggressive lymphoma  
*Alberto Orfao, Salamanca, ES*
- Meaning of MRD detection in treatment of lymphoma/CLL with new drugs  
*Paolo Ghia, Milano, IT*
- Abstract-based presentation  
(15 min)

10:00 – 10:30 *Coffee break*

### 10:30 – 11:45 **Session 5: MRD and Immune-monitoring**

*Chair: Tomasz Szczepański and Gianni Cazzaniga*

- Immune-monitoring in addition to MRD monitoring  
*Jacques J.M. van Dongen, Leiden, NL*
- CD19 targeted therapies: impact on normal and malignant cells  
*Claudia Rössig, Münster, DE*
- Abstract-based presentation  
(15 min)

### 11:45 – 12:45 **Session 6: Round Table Discussion**

*Moderator: Elizabeth Macintyre and Beat Schäfer.*

*Participants: t.b.d.*

*Topics:*

- Position of ddPCR
- Position of ctDNA in plasma vs cellular DNA
- Use of alternative (oncogenetic) targets vs IG/TR targets
- Meaning of MRD detection in treatment of lymphoma/CLL with new drugs
- Combining different MRD techniques like molecular and flow-based techniques: is this cost-effective?
- Combination of different approaches, such as MRD analysis and visualization (PET scans)
- Standard and new applications of MRD in treatment protocols

12:45 – 13:00 **Closing Remarks**

13:00 – 14:00 *Lunch*